Clinical trials: Sorafenib
Brain Tumor, Glioblastoma
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and best schedule of the combination of everolimus and sorafenib that can be given to patients with malignant glioma.
- Conditions
- Brain Tumor, Glioblastoma, Anaplastic Glioma
- Trial name
- NCT01434602
- Testing
- everolimus, sorafenib
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Pancreas Cancer
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
The purpose of this research is to determine the benefit of two oral chemotherapy drugs, Vemurafenib and Sorafenib, in individuals with KRAS mutated pancreatic cancer who have progressed on standard chemotherapy.
- Trial name
- NCT05068752
- Testing
- Vemurafenib, Sorafenib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- HonorHealth Research Institute
Carcinoma, Hepatocellular
Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria
This study is designed to determine whether proton beam radiotherapy plus Sorafenib compared to Sorafenib alone will produce the best results for treating patients with Hepatocellular Carcinoma.
- Trial name
- HCC (NCT01141478)
- Testing
- Proton Beam Radiotherapy, Sorafenib
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Loma Linda University
Carcinoma
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.
The purpose of this study is to compare treatment with RAD001 plus best supportive care (BSC) to placebo plus BSC in patients with advanced HCC whose disease progressed while on or after sorafenib treatment or who are intolerant…
- Trial name
- EVOLVE-1 (NCT01035229)
- Testing
- Everolimus, Best Supportive Care (BSC)
- Where
- 131 sites in United States, Australia and 16 more
- Volunteers
- 546 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Cancer
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00496756
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Nebraska
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Sorafenib in Myelodysplastic Syndrome
The purpose of this study is to evaluate the efficacy of sorafenib in patients with Myelodysplastic Syndrome (MDS). Eligible subjects will receive Sorafenib administered at 400mg orally twice a day, given on days 1-28 of a 28-day…
- Trial name
- NCT00510289
- Testing
- Sorafenib
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Duke University
Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia
Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
- Conditions
- Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia
- Trial name
- NCT00303966
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Renal Cell
Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)
A multicenter uncontrolled study of sorafenib in patients with unresectable and/or metastatic renal cell carcinoma (RCC) to assess the pharmacokinetic profile, safety and tolerability, and efficacy.
- Trial name
- NCT00586105
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 8 sites in China, Taiwan
- Volunteers
- 39 people
- Sponsor
- Bayer
Advanced Renal Cell Carcinoma
A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma
This is an open-label, randomized, controlled, multi-national, multi-center, parallel-arm trial comparing tivozanib to sorafenib in subjects with advanced RCC.
- Trial name
- TIVO-1 (NCT01030783)
- Testing
- tivozanib (AV-951), Sorafenib
- Where
- 86 sites in United States, Argentina and 14 more
- Volunteers
- 517 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Ovarian Neoplasm, Fallopian Tube Cancer
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer
Background: Sorafenib and bevacizumab are anti-cancer drugs that work by targeting the blood vessels that allow tumors to grow. Using the two drugs together may more effectively block the formation of blood vessels that feed…
- Conditions
- Ovarian Neoplasm, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT00436215
- Testing
- Bevacizumab, BAY 43-9006
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
Sorafenib has demonstrated in vivo anti-tumor efficacy. This trial will evaluate the safety and preliminary efficacy of sorafenib following chemoradiation in locally advanced NSCLC.
- Trial name
- NCT00417248
- Testing
- Cisplatin, Etoposide, Radiotherapy
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- Nasser Hanna, M.D.
Carcinoma, Hepatocellular
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and efficacy of doxorubicin plus sorafenib versus doxorubicin plus placebo in patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT00108953
- Testing
- Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin
- Where
- 28 sites in United States, Argentina and 4 more
- Volunteers
- 96 people
- Sponsor
- Bayer
Hepatocellular Cancer
Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer
The PI is studying if sorafenib/hydroxychloroquine (HCQ) will have improved efficacy when compared to sorafenib alone and in patients progressing of sorafenib the addition of HCQ would lead to disease stability in patients with…
- Trial name
- NCT03037437
- Testing
- Sorafenib (SOR), Hydroxychloroquine (HCQ)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
This phase I/II trial studies the side effects and best dose of sorafenib tosylate and bevacizumab and to see how well they work in treating patients with advanced kidney cancer.
- Conditions
- Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma
- Trial name
- NCT00126503
- Testing
- Bevacizumab, Sorafenib Tosylate, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 73 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Acute Myeloid Leukemia
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
There are 2 parts to this study: Part 1 (dose escalation) and Part 2 (dose expansion). The goal of Part 1 of this clinical research study is to find the highest tolerated dose of the combination of selinexor (KPT-330) and…
- Trial name
- NCT02530476
- Testing
- Selinexor, Sorafenib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
This research study will evaluate Sorafenib (Nexavar®) and Capecitabine (Xeloda®) to see the following: how effective this combination of study drugs will be in treating HCC how long subjects respond to these study drugs what…
- Trial name
- NCT01032850
- Testing
- Sorafenib & Capecitabine
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- New Mexico Cancer Research Alliance
Carcinoma, Renal Cell
BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma
The purpose of the study is to: Find out if patients receiving BAY43-9006 will live longer without tumor progression than those receiving standard therapy with interferon alpha-2a Find out if a higher dose of BAY43-9006 can…
- Trial name
- NCT00117637
- Testing
- Sorafenib (Nexavar, BAY43-9006), Interferon
- Where
- 42 sites in United States, France and 5 more
- Volunteers
- 189 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver
To determine if IMC-A12 given in combination with Sorafenib is safe and effective for participants with advanced liver cancer.
- Trial name
- NCT00906373
- Testing
- IMC-A12 (cixutumumab) - 10 milligrams/kilogram (mg/kg), IMC-A12 (cixutumumab) - 20 mg/kg, Sorafenib
- Where
- 7 sites in United States
- Volunteers
- 47 people
- Sponsor
- Eli Lilly and Company
Non-Small-Cell Lung Carcinoma
BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer
This study will investigate the effects and side effects of BAY 43-9006 in patients with advanced, recurrent, or refractory non-small cell lung cancer (NSCLC).
- Trial name
- NCT00098254
- Testing
- BAY 43-9006 (Sorafenib)
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Cancer
Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer
The purpose of this research study is to determine if sorafenib improves the effectiveness of a procedure called radiofrequency ablation (RFA) for the treatment of hepatocellular cancer (HCC).
- Trial name
- NCT00813293
- Testing
- Sorafenib, radiofrequency ablation
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Beth Israel Deaconess Medical Center